Predicting Development of SCAF in Device Patients

Launched by OTTAWA HEART INSTITUTE RESEARCH CORPORATION · Jun 20, 2016

Keywords

ClinConnect Summary

This clinical trial is focused on understanding how to predict the development of atrial fibrillation (AF) in patients who have implanted devices like pacemakers or defibrillators. Atrial fibrillation is a condition where the heart beats irregularly and can lead to serious issues like strokes. The researchers are trying to find out if certain proteins or chemical changes in the blood, known as biomarkers, can help identify people who are at risk of having early signs of atrial fibrillation. By detecting these signs early, doctors may be able to provide treatment to prevent the condition from becoming permanent.

To participate in this study, individuals must be aged 65 to 74 and have had a dual chamber permanent pacemaker or defibrillator implanted within the last 10 years. However, those with a documented history of atrial fibrillation, certain heart conditions, or who are pregnant or breastfeeding are not eligible. Participants will undergo regular monitoring of their heart rhythms through their implanted devices, and their blood will be tested to look for the biomarkers. This study could lead to new ways to identify and treat atrial fibrillation early, improving outcomes for many patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • • Dual chamber permanent pacemaker or defibrillator implanted within previous 10 years
• Exclusion Criteria:
• • Clinical atrial fibrillation documented by surface ECG (12 lead ECG, Telemetry, Holter)
• • Participants considered by the investigator to be unsuitable for the study for the following reason: life expectancy less than 2 years due to concomitant disease
• • Participants who are pregnant or breast-feeding
• • Congenital heart disease
• • Inherited arrhythmia syndrome, i.e. Brugada, long QT interval